Literature DB >> 19955045

Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Maria Knoph Kvamme1, Ivar Sønbø Kristiansen, Elisabeth Lie, Tore Kristian Kvien.   

Abstract

OBJECTIVE: To identify cutpoints reflecting Patient Acceptable Symptom State (PASS) and Minimal Clinically Important Improvement (MCII) in patient-reported multi-attribute health status classification systems and health status measurements among patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).
METHODS: We identified patients with RA, AS, and PsA from the Norwegian disease-modifying antirheumatic drug (DMARD) register (NOR-DMARD). The patients (n = 4225) had started with DMARD and responded to the PASS and MCII anchoring questions at the 3-month followup examination. Receiver operating characteristics (ROC) curves with 80% specificity and the 75th percentile approach were used to identify PASS and MCII cutpoints in the EuroQol-5 Dimensions (EQ-5D) and the Short-Form-6 Dimensions (SF-6D) indexes, but also in other patient-reported outcomes (joint pain and patient global visual analog scale and Modified Health Assessment Questionnaire).
RESULTS: The PASS cutpoints estimated with 80% specificity were around 0.70 in EQ-5D in all diseases and around 0.65 in SF-6D. The cutpoints were around 0.65 and 0.60, respectively, when the 75th percentile approach was used. The MCII cutpoints assessed by 80% specificity varied from 0.10 to 0.19 in EQ-5D and from 0.07 to 0.10 in SF-6D.
CONCLUSION: The cutpoints for PASS in EQ-5D and SF-6D indicate that PASS corresponds to a health-related quality of life that is far from perfect health. Somewhat different cutpoints were identified for both PASS and MCII with 80% specificity versus the 75th percentile method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955045     DOI: 10.3899/jrheum.090449

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

2.  Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.

Authors:  Jos Hendrikx; Jaap Fransen; Wietske Kievit; Piet L C M van Riel
Journal:  Qual Life Res       Date:  2014-09-25       Impact factor: 4.147

3.  Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity.

Authors:  Nasim A Khan; Horace J Spencer; Esam Abda; Amita Aggarwal; Rieke Alten; Codrina Ancuta; Daina Andersone; Martin Bergman; Jurgen Craig-Muller; Jacqueline Detert; Lia Georgescu; Laure Gossec; Hisham Hamoud; Johannes W G Jacobs; Ieda Maria Magalhaes Laurindo; Maria Majdan; Antonio Naranjo; Sapan Pandya; Christof Pohl; Georg Schett; Zahraa I Selim; Sergio Toloza; Hisahi Yamanaka; Tuulikki Sokka
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

Review 4.  Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.

Authors:  Amanda J Steiman; Janet E Pope; Heather Thiessen-Philbrook; Lihua Li; Cheryl Barnabe; Fares Kalache; Tabitha Kung; Louis Bessette; Cathy Flanagan; Boulos Haraoui; Jacqueline Hochman; Sharon Leclercq; Dianne Mosher; Carter Thorne; Vivian Bykerk
Journal:  Rheumatol Int       Date:  2013-01-06       Impact factor: 2.631

5.  Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Ann Rheum Dis       Date:  2014-05-01       Impact factor: 19.103

6.  Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis.

Authors:  Michael M Ward; Isabel Castrejon; Martin J Bergman; Maria I Alba; Lori C Guthrie; Theodore Pincus
Journal:  J Rheumatol       Date:  2018-10-15       Impact factor: 4.666

Review 7.  [Treat-to-target from the patient perspective].

Authors:  E Gromnica-Ihle; M Rink
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

8.  Domain-specific transition questions demonstrated higher validity than global transition questions as anchors for clinically important improvement.

Authors:  Michael M Ward; Lori C Guthrie; Maria Alba
Journal:  J Clin Epidemiol       Date:  2015-02-11       Impact factor: 6.437

9.  Long-term utility outcomes in patients undergoing endoscopic sinus surgery.

Authors:  Luke Rudmik; Jess Mace; Zachary M Soler; Timothy L Smith
Journal:  Laryngoscope       Date:  2013-05-13       Impact factor: 3.325

10.  Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Authors:  Michael B Arnold; Dinesh Khanna; Christopher P Denton; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Helen Spotswood; Laura Burke; Jeffrey Siegel; Angelika Jahreis; Daniel E Furst; Janet E Pope
Journal:  Rheumatology (Oxford)       Date:  2018-01-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.